Lowe, Scott W.

Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018.

Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation

Cell death mechanisms and regulationAutophagy in Disease and Therapy

Cited by 6,680

Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a

Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell

Telomeres, Telomerase, and SenescenceCancer-related Molecular Pathways

Cited by 5,218

p53 is required for radiation-induced apoptosis in mouse thymocytes

Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., & Jacks, T. (1993) · Nature

Cancer-related Molecular PathwaysCell death mechanisms and regulation

Cited by 2,864

A microRNA component of the p53 tumour suppressor network

He, L., He, X., Lim, L. P., de Stanchina, E., Xuan, Z., Liang, Y., Xue, W., Zender, L., Magnus, J., Ridzon, D., et al. (2007) · Nature

MicroRNA in disease regulationCancer-related Molecular Pathways

Cited by 2,692

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature

Cancer-related Molecular PathwaysTelomeres, Telomerase, and Senescence

Cited by 2,473

Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours

Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J. (1996) · Nature

Cell death mechanisms and regulationCancer, Hypoxia, and Metabolism

Cited by 2,300

Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence

Narita, M., Nuñez, S., Heard, E., Narita, M., Lin, A. W., Hearn, S. A., Spector, D. L., Hannon, G. J., & Lowe, S. W. (2003) · Cell

Telomeres, Telomerase, and SenescenceGenomics and Chromatin Dynamics

Cited by 2,278

Senescence of Activated Stellate Cells Limits Liver Fibrosis

Krizhanovsky, V., Yon, M., Dickins, R. A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., & Lowe, S. W. (2008) · Cell

Liver physiology and pathologyTelomeres, Telomerase, and Senescence

Cited by 2,027

Putting p53 in context

Kastenhuber, E. R., & Lowe, S. W. (2017) · Cell

Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 1,906

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature

Protein Degradation and InhibitorsAcute Myeloid Leukemia Research

Cited by 1,870

Reversal of human cellular senescence: roles of the p53 and p16 pathways

Beauséjour, C. M., Krtolica, A., Galimi, F., Narita, M., Lowe, S. W., Yaswen, P., & Campisi, J. (2003) · The EMBO Journal

Telomeres, Telomerase, and SenescenceCancer-related Molecular Pathways

Cited by 1,457

Control of apoptosis by p53

Fridman, J. S., & Lowe, S. W. (2003) · Oncogene

Cancer-related Molecular PathwaysCell death mechanisms and regulation

Cited by 1,401

Senolytic CAR T cells reverse senescence-associated pathologies

Amor, C., Feucht, J., Leibold, J., Ho, Y.-J., Zhu, C., Alonso-Curbelo, D., Mansilla-Soto, J., Boyer, J. A., Li, X., Giavridis, T., et al. (2020) · Nature

Telomeres, Telomerase, and SenescenceCAR-T cell therapy research

Cited by 1,098

The microcosmos of cancer

Lujambio, A., & Lowe, S. W. (2012) · Nature

MicroRNA in disease regulationCancer-related molecular mechanisms research

Cited by 1,084

Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach

Zender, L., Spector, M. S., Xue, W., Flemming, P., Cordon-Cardo, C., Silke, J., Fan, S.-T., Luk, J. M., Wigler, M., Hannon, G. J., et al. (2006) · Cell

Cancer Genomics and DiagnosticsHippo pathway signaling and YAP/TAZ

Cited by 1,065

A Senescence Program Controlled by p53 and p16INK4a Contributes to the Outcome of Cancer Therapy

Schmitt, C. A., Fridman, J. S., Yang, M., Lee, S., Baranov, E., Hoffman, R. M., & Lowe, S. W. (2002) · Cell

Telomeres, Telomerase, and SenescenceCancer-related Molecular Pathways

Cited by 1,050

Control of the senescence-associated secretory phenotype by NF-κB promotes senescence and enhances chemosensitivity

Chien, Y., Scuoppo, C., Wang, X., Fang, X., Balgley, B., Bolden, J. E., Premsrirut, P., Luo, W., Chicas, A., Lee, C. S., et al. (2011) · Genes & Development

Telomeres, Telomerase, and SenescenceNF-κB Signaling Pathways

Cited by 1,046

Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling

Lin, A. W., Barradas, M., Stone, J. C., van Aelst, L., Serrano, M., & Lowe, S. W. (1998) · Genes & Development

Telomeres, Telomerase, and SenescenceCancer-related Molecular Pathways

Cited by 945

p53-Dependent apoptosis suppresses tumor growth and progression in vivo

Symonds, H., Krall, L., Remington, L., Saenz-Robles, M., Lowe, S., Jacks, T., & Van Dyke, T. (1994) · Cell

Cancer-related Molecular PathwaysCell death mechanisms and regulation

Cited by 880

Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway

Freed-Pastor, W. A., Mizuno, H., Zhao, X., Langerød, A., Moon, S.-H., Rodriguez-Barrueco, R., Barsotti, A., Chicas, A., Li, W., Polotskaia, A., et al. (2012) · Cell

Cancer, Lipids, and MetabolismCancer-related Molecular Pathways

Cited by 865

Non-Cell-Autonomous Tumor Suppression by p53

Lujambio, A., Akkari, L., Simon, J., Grace, D., Tschaharganeh, D. F., Bolden, J. E., Zhao, Z., Thapar, V., Joyce, J. A., Krizhanovsky, V., et al. (2013) · Cell

Telomeres, Telomerase, and SenescenceCancer-related Molecular Pathways

Cited by 766

Tumor suppression by Ink4a-Arf: progress and puzzles.

Lowe, S. W., & Sherr, C. J. (2003) · Current Opinion in Genetics & Development

Cancer-related Molecular PathwaysTelomeres, Telomerase, and Senescence

Cited by 699

In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system

Maddalo, D., Manchado, E., Concepcion, C. P., Bonetti, C., Vidigal, J. A., Han, Y.-C., Ogrodowski, P., Crippa, A., Rekhtman, N., de Stanchina, E., et al. (2014) · Nature

CRISPR and Genetic EngineeringCancer Genomics and Diagnostics

Cited by 640

The Regulation of AMPK β1, TSC2, and PTEN Expression by p53: Stress, Cell and Tissue Specificity, and the Role of These Gene Products in Modulating the IGF-1-AKT-mTOR Pathways

Feng, Z., Hu, W., de Stanchina, E., Teresky, A. K., Jin, S., Lowe, S., & Levine, A. J. (2007) · Cancer Research

PI3K/AKT/mTOR signaling in cancerMetabolism, Diabetes, and Cancer

Cited by 633